These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9629880)

  • 1. Statistical considerations in the design, conduct and analyses of antiemetic clinical trials. An emerging consensus.
    Morrow GR; Ballatori E; Groshen S; Olver I
    Support Care Cancer; 1998 May; 6(3):261-5. PubMed ID: 9629880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consensus regarding multiple day and rescue antiemetic therapy.
    De Mulder PH; Roila F; Kris MG; Marty MM
    Support Care Cancer; 1998 May; 6(3):248-52. PubMed ID: 9629878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity.
    Hesketh PJ; Gralla RJ; du Bois A; Tonato M
    Support Care Cancer; 1998 May; 6(3):221-7. PubMed ID: 9629873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marijuana as an antiemetic drug: how useful is it today? Opinions from clinical oncologists.
    Schwartz RH; Beveridge RA
    J Addict Dis; 1994; 13(1):53-65. PubMed ID: 7503819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed emesis following anticancer chemotherapy.
    Kris MG; Roila F; De Mulder PH; Marty M
    Support Care Cancer; 1998 May; 6(3):228-32. PubMed ID: 9629874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiemetic study design: desirable objectives, stratifications and analyses.
    Olver IN
    Br J Cancer Suppl; 1992 Dec; 19():S30-3; discussion S33-4. PubMed ID: 1467198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New aspects in the prevention and therapy of cytostatic drug-induced nausea and vomiting].
    Evers C; Riess H
    Z Arztl Fortbild (Jena); 1992 Sep; 86(17):847-53. PubMed ID: 1413901
    [No Abstract]   [Full Text] [Related]  

  • 8. New directions in managing chemotherapy-related emesis.
    Krasnow SH
    Oncology (Williston Park); 1991 Sep; 5(9 Suppl):19-24. PubMed ID: 1836346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Problems in antiemetic trial design and interpretation.
    Krasnow SH
    Oncology (Williston Park); 1989 Aug; 3(8 Suppl):5-10. PubMed ID: 2701576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study design for the evaluation of the efficacy and safety of nabilone.
    Stark P
    Cancer Treat Rev; 1982 Dec; 9 Suppl B():35-7. PubMed ID: 6299553
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacological management of chemotherapy-induced nausea and vomiting in children with cancer.
    Cefalo MG; Ruggiero A; Maurizi P; Attinà G; Arlotta A; Riccardi R
    J Chemother; 2009 Dec; 21(6):605-10. PubMed ID: 20071282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticosteroids, dopamine antagonists and other drugs.
    Herrstedt J; Aapro MS; Smyth JF; Del Favero A
    Support Care Cancer; 1998 May; 6(3):204-14. PubMed ID: 9629871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A survey of antiemetic use in children with cancer.
    van Hoff J; Hockenberry-Eaton MJ; Patterson K; Hutter JJ
    Am J Dis Child; 1991 Jul; 145(7):773-8. PubMed ID: 2058609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiemetics: an update and the MASCC guidelines applied in clinical practice.
    Herrstedt J
    Nat Clin Pract Oncol; 2008 Jan; 5(1):32-43. PubMed ID: 18097455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiemetic agents.
    Wilkes G
    Oncology (Williston Park); 2007 Jul; 21(8 Suppl):48. PubMed ID: 17844897
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiemetic therapy in patients treated with cisplatin chemotherapy.
    Roila F; Basurto C; Bracarda S; Del Favero A; Tonato M
    J Chemother; 1989 Jul; 1(4 Suppl):1281-5. PubMed ID: 16312866
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of aprepitant among patients aged 65 and over receiving moderately to highly emetogenic chemotherapy: a meta-analysis of unpublished data from previously published studies.
    Chapell R; Aapro MS
    J Geriatr Oncol; 2013 Jan; 4(1):78-83. PubMed ID: 24071495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Special feature: in quest of an effective antiemetic in cancer chemotherapy. Research with antiemetics for cancer chemotherapy: problems and possibilities.
    Maxwell MB
    Oncol Nurs Forum; 1982; 9(3):11-6. PubMed ID: 7050931
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.